CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...